New CODP treatment gets FDA nod

Nov 12, 2018

Mylan and Theravance Biopharma have won approval for their inhalable treatment, Yupelri. 

Designed as a maintenance treatment for patients with chronic obstructive pulmonary disease, Yupelri is the first-ever once-daily, nebulized bronchodilator approved by the FDA for COPD. 

Around 16 million Americans have COPD, and the companies say that 9-10 percent of patients prefer a nebulized product to treat the condition. 

The companies plan to launch Yupelri in the U.S. later this year.  

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!